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Small cell lung cancer (SCLC) is a high grade poorly
differentiated neuroendocrine carcinoma of the lung
responsible forw15% of diagnosed lung cancers and up
to 25% of lung cancer deaths. Treatment paradigms in
small cell lung cancer have not changed signiﬁcantly in
the last 20 years. Advances in targeted therapies for
SCLC are sorely needed. Somatostatin receptors (SSTR)
are neuroendocrine associated G protein-coupled re-
ceptors associated with multiple tumor types and which
have effects on cell cycling, angiogenesis, apoptosis, and
growth factors. They canonically signal by inhibition of
adenylate cyclase, calcium inﬂux, and act through
downstream MAPK and Akt as well as other downstream
kinases. We evaluated SSTR2 expression by IHC staining
and western blotting of multiple cell lines and tumor
tissues and found high expression in multiple neuroen-
docrine lung carcinomas including classical and variant
SCLC lines. Given the high level of SSTR2 expression
found in most SCLC lines, we hypothesized that this
signaling pathway stimulates growth and survival of
these tumor cells. We followed these preliminary studies
with an assessment of 98 SCLC patients whose tumor
IHC was subdivided into high or low SSTR2 expressing
tumors by continuous IHC scoring. Low SSTR2 tumors
had a better prognosis with a median survival in limited
stage disease of 36 months compared to 12 months in
the SSTR2 high expressing SCLCs suggesting that SSTR2
expression has clinical relevance in SCLC progression.
The hazard ratio was 0.45 with a p<0.05. This led to
further experiment to interrogate the mechanism and
function of SSTR2 in SCLC. We established multiple
stable SSTR2 shRNA knockdown lines including bron-
chial carcinoid, and multiple adherent SCLC lines. SSTR2
knockdown led to up to 3 fold changes in cell viability
in vitro with reduced proliferation in multiple cell cul-
ture lines and constructs as well as apoptosis in H1048
cells. Metabolic testing with Seahorse mito stress kitsconcurred with signiﬁcant differences in mitochondrial
respiration and metabolic activity in the SSTR2 knock-
down cell lines with a slightly increased basal metabolic
rate and a signiﬁcant greater than 75% increase in
maximal respiration compared to the control scrambled
construct cell line. We are actively pursuing metabolic
studies in SCLC and will expand this work to evaluate
ADP/ATP and AMP/ATP ratios to determine if aberrant
energy homeostasis may contribute to the observed cell
death in this metabolically active cell population.
Collectively, this data brings new interest to SSTR2
signaling as a pathway target for therapy in a subset of
SCLC and suggests potential metabolic targets in SCLC.An epigenetic switch leads to EMT
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Metastases are the major causes of death in cancer pa-
tients. Prevention and therapy against metastatic or
dormant tumor cells have achieved limited success due
to gaps in our knowledge regarding the underlying
mechanisms. Dysregulated inﬂammation is associated
with the development and progression of lung cancer.
Lung cancer patients with increased levels of inﬂam-
matory mediators or inﬂammatory cells have poorer
outcomes. It has been shown that inﬂammatory cyto-
kines in the tumor microenvironment can promote
cancer metastasis and facilitate formation of stem-like
malignant cells. However, the mechanisms of these ef-
fects in lung cancer have not been fully understood.
Recently, we have found that a subset of NSCLC cells
undergo epithelial-to-mesenchymal transition (EMT) in
the presence of cytokines including IL-1b, TNF-a and
TGF-b (within 7 days). This occurs concomitantly with
increased cell migration and invasion. Surprisingly,
chronic exposure to these inﬂammatory cytokines leads
to EMT memory, referring to the phenomenon that cells
are able to maintain EMT despite withdrawal of the
original stimulus. Intriguingly, EMT memory cannot be
induced by acute cytokine exposure and the signaling
pathways (JNK/ERK) and transcription factors (fra-1/
slug) mediating the acute EMT are necessary to establish
but not required to maintain EMT memory. Further
studies demonstrated that EMT memory is due to a dy-
namic alteration of histone modiﬁcations and subse-
quent DNA methylation during chronic IL-1b exposure.
Importantly, EMT memory also allows cells to irrevers-
ibly become migratory and invasive. In a pilot study, we
